Citation Impact
Citing Papers
Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
2012
Spatially resolved, highly multiplexed RNA profiling in single cells
2015 StandoutScience
Ubiquitylated PCNA plays a role in somatic hypermutation and class-switch recombination and is required for meiotic progression
2008
Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
2012
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Isothermal amplified detection of DNA and RNA
2014
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
2009
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
2017 Standout
Comprehensive molecular portraits of human breast tumours
2012 StandoutNature
DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study
2012
Triple negative tumours: a critical review
2007
Evaluation of non-invasive prenatal testing (NIPT) for aneuploidy in an NHS setting: a reliable accurate prenatal non-invasive diagnosis (RAPID) protocol
2014
The promise and challenge of therapeutic genome editing
2020 StandoutNatureNobel
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
2011 Standout
Triple-Negative Breast Cancer
2010 Standout
The DNA-damage response in human biology and disease
2009 StandoutNature
Pancreatic cancer
2004 Standout
DNA Sequencing versus Standard Prenatal Aneuploidy Screening
2014 Standout
Genome-Wide Fetal Aneuploidy Detection by Maternal Plasma DNA Sequencing
2012
A view on drug resistance in cancer
2019 StandoutNature
Ferroptosis as a p53-mediated activity during tumour suppression
2015 StandoutNature
PARP inhibitor combination therapy
2016
ACMG statement on noninvasive prenatal screening for fetal aneuploidy
2013
Expanding the Biologist’s Toolkit with CRISPR-Cas9
2015 StandoutNobel
Ovarian cancer
2014 Standout
Mechanism of somatic hypermutation: Critical analysis of strand biased mutation signatures at A:T and G:C base pairs
2008
Olaparib: First Global Approval
2015
Spatially resolved transcriptomics and beyond
2014
Modulation of oxidative stress as an anticancer strategy
2013 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Pancreatic cancer
2016 Standout
Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population
2012
Phosphoinositide 3-Kinase Regulates Glycolysis through Mobilization of Aldolase from the Actin Cytoskeleton
2016
Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC)
2016
In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system
2014 Nature
Cell-free DNA Analysis for Noninvasive Examination of Trisomy
2015 Standout
Chromosome-selective sequencing of maternal plasma cell–free DNA for first-trimester detection of trisomy 21 and trisomy 18
2012
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
2010 Standout
DNA sequencing of maternal plasma to detect Down syndrome: An international clinical validation study
2011
Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status
2010
Activation-induced cytidine deaminase structure and functions: A species comparative view
2011
Combined immune checkpoint blockade as a therapeutic strategy for BRCA1 -mutated breast cancer
2017
Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18
2012
Balancing AID and DNA repair during somatic hypermutation
2009
Liquid biopsies come of age: towards implementation of circulating tumour DNA
2017 Standout
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Mechanisms of resistance to therapies targeting BRCA-mutant cancers
2013
FAST-SeqS: A Simple and Efficient Method for the Detection of Aneuploidy by Massively Parallel Sequencing
2012
Single-Nucleotide Polymorphism–Based Noninvasive Prenatal Screening in a High-Risk and Low-Risk Cohort
2014
The DNA damage response and cancer therapy
2012 Nature
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18
2012
Maternal Plasma Cell-Free Fetal and Maternal DNA at 11-13 Weeks' Gestation: Relation to Fetal and Maternal Characteristics and Pregnancy Outcomes
2013
Modeling and predicting clinical efficacy for drugs targeting the tumor milieu
2012
Synthetic lethality: the road to novel therapies for breast cancer
2016
Therapeutic potential of PARP inhibitors for metastatic breast cancer
2011
From prenatal genomic diagnosis to fetal personalized medicine: progress and challenges
2012
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
2012 Standout
Synthetic lethality and cancer
2017
The Hallmarks of Aging
2013 Standout
CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes
2016 Standout
The PI3K Pathway in Human Disease
2017 Standout
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
2010 Standout
Noncanonical Mismatch Repair as a Source of Genomic Instability in Human Cells
2012
Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection
2016 StandoutNatureNobel
Deconstructing the molecular portraits of breast cancer
2010
Pancreatic cancer
2011 Standout
The mutant p53 mouse as a pre-clinical model
2013
Genome-editing revolution: My whirlwind year with CRISPR
2015 StandoutNatureNobel
Carboxy-terminal domain of AID required for its mRNA complex formation in vivo
2009 StandoutNobel
Down Syndrome
2020 Standout
SNP‐based non‐invasive prenatal testing detects sex chromosome aneuploidies with high accuracy
2013
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Position statement from the Aneuploidy Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis
2013
Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer
2015
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
2016
DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition
2009 Standout
Identification of DNA cleavage- and recombination-specific hnRNP cofactors for activation-induced cytidine deaminase
2015 StandoutNobel
Selective analysis of cell‐free DNA in maternal blood for evaluation of fetal trisomy
2012
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
2012
DNA polymerase ζ generates tandem mutations in immunoglobulin variable regions
2012
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems
2016 StandoutScience
Genomic Engineering and the Future of Medicine
2015 StandoutNobel
An Evolutionary View of the Mechanism for Immune and Genome Diversity
2012 StandoutNobel
Circulating Fetal Cell-Free DNA Fractions Differ in Autosomal Aneuploidies and Monosomy X
2013
Cytokine Storm
2020 Standout
PMS2 endonuclease activity has distinct biological functions and is essential for genome maintenance
2010 StandoutNobel
Recent Developments in the Preparation and Chemistry of Metallacycles and Metallacages via Coordination
2015 Standout
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Topoisomerase levels determine chemotherapy response in vitro and in vivo
2008
The Biochemistry of Somatic Hypermutation
2008
The DNA-damage response: new molecular insights and new approaches to cancer therapy
2009
Differential regulation of S-region hypermutation and class-switch recombination by noncanonical functions of uracil DNA glycosylase
2014 StandoutNobel
Cancer Genome Landscapes
2013 StandoutScience
Analysis of cell‐free DNA in maternal blood in screening for fetal aneuploidies: updated meta‐analysis
2015
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Preterm labor: One syndrome, many causes
2014 StandoutScience
Coordination-Driven Self-Assembly and Anticancer Potency Studies of Arene–Ruthenium-Based Molecular Metalla-Rectangles
2014
Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy
2009
Extrahelical (CAG)/(CTG) triplet repeat elements support proliferating cell nuclear antigen loading and MutLα endonuclease activation
2013 StandoutNobel
First‐trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell‐free DNA testing
2013
APE1 is dispensable for S-region cleavage but required for its repair in class switch recombination
2014 StandoutNobel
Implementation of maternal blood cell‐free DNA testing in early screening for aneuploidies
2013
Circulating cell free DNA testing: are some test failures informative?
2014
Maternal cfDNA screening for Down syndrome – a cost sensitivity analysis
2013
Functional requirements of AID’s higher order structures and their interaction with RNA-binding proteins
2016 StandoutNobel
Noninvasive prenatal testing of fetal aneuploidies by massively parallel sequencing in a prospective Chinese population
2013
Optimal Detection of Fetal Chromosomal Abnormalities by Massively Parallel DNA Sequencing of Cell-Free Fetal DNA from Maternal Blood
2011
Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1 -mutated basal-like breast cancer
2007
Etoposide Selectively Ablates Activated T Cells To Control the Immunoregulatory Disorder Hemophagocytic Lymphohistiocytosis
2013
Works of Anders O.H. Nygren being referenced
Poly(ADP-Ribose) Polymerase-1 Inhibitor Treatment Regresses Autochthonous Brca2/p53 -Mutant Mammary Tumors In vivo and Delays Tumor Relapse in Combination with Carboplatin
2009
Moderate Increase in Mdr1a/1b Expression Causes In vivo Resistance to Doxorubicin in a Mouse Model for Hereditary Breast Cancer
2009
Sensitivity and Acquired Resistance of BRCA1;p53-Deficient Mouse Mammary Tumors to the Topoisomerase I Inhibitor Topotecan
2010
Identification of Genomic Deletions of the APC Gene in Familial Adenomatous Polyposis by Two Independent Quantitative Techniques
2004
Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting
2011
In situ genotyping individual DNA molecules by target-primed rolling-circle amplification of padlock probes
2004
Ultrasensitive Detection of Multiplexed Somatic Mutations Using MALDI-TOF Mass Spectrometry
2015
Quantification of Fetal DNA by Use of Methylation-Based DNA Discrimination
2010
A/T mutagenesis in hypermutated immunoglobulin genes strongly depends on PCNAK164 modification
2007
Noninvasive Detection of Fetal Trisomy 21 by Sequencing of DNA in Maternal Blood: A Study in a Clinical Setting
2011
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
2008
Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer
2007